MDWD vs. TELO, CLSD, IMUX, GLYC, CARM, COYA, CRVS, IFRX, CDTX, and LPTX
Should you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Telomir Pharmaceuticals (TELO), Clearside Biomedical (CLSD), Immunic (IMUX), GlycoMimetics (GLYC), Carisma Therapeutics (CARM), Coya Therapeutics (COYA), Corvus Pharmaceuticals (CRVS), InflaRx (IFRX), Cidara Therapeutics (CDTX), and Leap Therapeutics (LPTX). These companies are all part of the "medical" sector.
MediWound (NASDAQ:MDWD) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
MediWound received 388 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.
Telomir Pharmaceuticals has lower revenue, but higher earnings than MediWound.
46.8% of MediWound shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Telomir Pharmaceuticals has a net margin of 0.00% compared to MediWound's net margin of -35.94%. Telomir Pharmaceuticals' return on equity of 0.00% beat MediWound's return on equity.
In the previous week, MediWound had 8 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 11 mentions for MediWound and 3 mentions for Telomir Pharmaceuticals. MediWound's average media sentiment score of 0.67 beat Telomir Pharmaceuticals' score of 0.62 indicating that MediWound is being referred to more favorably in the media.
MediWound presently has a consensus target price of $32.00, indicating a potential upside of 124.56%. Given MediWound's higher probable upside, equities analysts clearly believe MediWound is more favorable than Telomir Pharmaceuticals.
Summary
MediWound beats Telomir Pharmaceuticals on 8 of the 11 factors compared between the two stocks.
Get MediWound News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
MediWound Competitors List
Related Companies and Tools